Peptides genetically selected for NF-κB activation cooperate with oncogene Ras and model carcinogenic role of inflammation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 4, 2014, Pages

  Natarajan, Venkatesh ^a   Komarov, Andrei P ^b   Ippolito, Thomas ^a   Bonneau, Kyle ^b   Chenchik, Alex A ^b   Gudkov, Andrei V ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Cellecta Inc   (United States)

Author keywords

Functional genomics; TRAF6

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEPTIDE;

ANIMAL CELL; ARTICLE; CARCINOGENIC ACTIVITY; CELL TRANSFORMATION; CONTROLLED STUDY; EMBRYO; ENDOPLASMIC RETICULUM; FIBROBLAST; GENE ACTIVATION; IN VITRO STUDY; INFLAMMATION; NONHUMAN; OLIGOMERIZATION; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN ISOLATION; RAT;

FUNCTIONAL GENOMICS; TRAF6;

AMINO ACID SEQUENCE; ANIMALS; CARCINOGENESIS; CELLS, CULTURED; GENES, RAS; HUMANS; INFLAMMATION; MICE; MOLECULAR SEQUENCE DATA; NF-KAPPA B; PEPTIDES; PROTEIN BINDING; RATS;

EID: 84893412609     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1311945111     Document Type: Article

References (51)

1. KarinM(2006) Nuclear factor-kappaB in cancer development and progression. Nature 441(7092):431-436.
2. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436-444.
3. Balkwill F (2004) Cancer and the chemokine network. Nat Rev Cancer 4(7):540-550.
4. Dranoff G (2004) Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4(1):11-22.
5. Mantovani A (2005) Cancer: Inflammation by remote control. Nature 435(7043): 752-753.
6. Allavena P, Garlanda C, Borrello MG, Sica A, Mantovani A (2008) Pathways connecting inflammation and cancer. Curr Opin Genet Dev 18(1):3-10.
7. Mantovani A (2009) Cancer: Inflaming metastasis. Nature 457(7225):36-37.
8. Gudkov AV, Gurova KV, Komarova EA (2011) Inflammation and p53: A tale of two stresses. Genes Cancer 2(4):503-516.
9. Ghosh S, Hayden MS (2012) Celebrating 25 years of NF-κB research. Immunol Rev 246(1):5-13.
10. Karin M, Greten FR (2005) NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5(10):749-759.
11. Karin M (2009) NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol 1(5):a000141.
12. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883-899.
13. Komarova EA, et al. (2005) p53 is a suppressor of inflammatory response in mice. FASEB J 19(8):1030-1032.
14. Gurova KV, et al. (2005) Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci USA 102(48):17448-17453.
15. Ak P, Levine AJ (2010) p53 and NF-κB: Different strategies for responding to stress lead to a functional antagonism. FASEB J 24(10):3643-3652.
16. Prives C, Hall PA (1999) The p53 pathway. J Pathol 187(1):112-126.
17. Lane D, Levine A (2010) p53 Research: The past thirty years and the next thirty years. Cold Spring Harb Perspect Biol 2(12):a000893.
18. Nelson DE, et al. (2004) Oscillations in NF-kappaB signaling control the dynamics of gene expression. Science 306(5696):704-708.
19. Ashall L, et al. (2009) Pulsatile stimulation determines timing and specificity of NFkappaB- dependent transcription. Science 324(5924):242-246.
20. Chenchik A, Gudkov A, Komarov A, Natarajan V (2010) US Patent Appl 20100305002 A1.
21. Hunter T (1991) Cooperation between oncogenes. Cell 64(2):249-270.
22. Harbury PB, Zhang T, Kim PS, Alber T (1993) A switch between two-, three-, and fourstranded coiled coils in GCN4 leucine zipper mutants. Science 262(5138):1401-1407.
23. Zhang N, et al. (2005) Regulation of IkBa expression involves both NF-kB and the MAP kinase signaling pathways. J Inflamm (Lond) 2:10.
24. Burdelya LG, et al. (2013) Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist. Proc Natl Acad Sci USA 110(20):E1857-E1866.
25. Baud V, Karin M (2001) Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 11(9):372-377.
26. Boiko AD, et al. (2006) A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation. Genes Dev 20(2):236-252.
27. Ossovskaya VS, et al. (1996) Use of genetic suppressor elements to dissect distinct biological effects of separate p53 domains. Proc Natl Acad Sci USA 93(19): 10309-10314.
28. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88(5):593-602.
29. Dimri GP, et al. (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92(20):9363-9367.
30. Logunov DY, et al. (2008) Mycoplasma infection suppresses p53, activates NF-kappaB and cooperates with oncogenic Ras in rodent fibroblast transformation. Oncogene 27(33):4521-4531.
31. Baldi L, Brown K, Franzoso G, Siebenlist U (1996) Critical role for lysines 21 and 22 in signal-induced, ubiquitin-mediated proteolysis of I kappa B-alpha. J Biol Chem 271(1): 376-379.
32. Komarova EA, et al. (1997) Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J 16(6):1391-1400.
33. Karin M (2008) The IkappaB kinase: A bridge between inflammation and cancer. Cell Res 18(3):334-342.
34. Karin M, Lawrence T, Nizet V (2006) Innate immunity gone awry: Linking microbial infections to chronic inflammation and cancer. Cell 124(4):823-835.
35. Chu ZL, et al. (1997) Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci USA 94(19): 10057-10062.
36. Lu T, Sathe SS, Swiatkowski SM, Hampole CV, Stark GR (2004) Secretion of cytokines and growth factors as a general cause of constitutive NFkappaB activation in cancer. Oncogene 23(12):2138-2145.
37. Iosef C, et al. (2012) Inhibiting NF-κB in the developing lung disrupts angiogenesis and alveolarization. Am J Physiol Lung Cell Mol Physiol 302(10):L1023-L1036.
38. Hayden MS, Ghosh S (2008) Shared principles in NF-kappaB signaling. Cell 132(3): 344-362.
39. Baud V, et al. (1999) Signaling by proinflammatory cytokines: Oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain. Genes Dev 13(10):1297-1308.
40. Oeckinghaus A, Hayden MS, Ghosh S (2011) Crosstalk in NF-κB signaling pathways. Nat Immunol 12(8):695-708.
41. Wu H, Arron JR (2003) TRAF6, a molecular bridge spanning adaptive immunity, innate immunity and osteoimmunology. Bioessays 25(11):1096-1105.
42. Liu H, et al. (2012) TRAF6 activation in multiple myeloma: A potential therapeutic target. Clin Lymphoma Myeloma Leuk 12(3):155-163.
43. Mayo MW, et al. (1997) Requirement of NF-kappaB activation to suppress p53- independent apoptosis induced by oncogenic Ras. Science 278(5344):1812-1815.
44. Kawauchi K, Araki K, Tobiume K, Tanaka N (2008) p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol 10(5):611-618.
45. Tergaonkar V, Pando M, Vafa O, Wahl G, Verma I (2002) p53 stabilization is decreased upon NFkappaB activation: A role for NFkappaB in acquisition of resistance to chemotherapy. Cancer Cell 1(5):493-503.
46. Ryan KM, Ernst MK, Rice NR, Vousden KH (2000) Role of NF-kappaB in p53-mediated programmed cell death. Nature 404(6780):892-897.
47. Ravi R, et al. (1998) p53-mediated repression of nuclear factor-kappaB RelA via the transcriptional integrator p300. Cancer Res 58(20):4531-4536.
48. Kawauchi K, Araki K, Tobiume K, Tanaka N (2009) Loss of p53 enhances catalytic activity of IKKbeta through O-linked beta-N-acetyl glucosamine modification. Proc Natl Acad Sci USA 106(9):3431-3436.
49. Gudkov AV, Komarova EA (2010) Pathologies associated with the p53 response. Cold Spring Harb Perspect Biol 2(7):a001180.
50. Roninson IB, et al. (1995) Genetic suppressor elements: New tools for molecular oncology-thirteenth Cornelius P. Rhoads Memorial Award Lecture. Cancer Res 55(18):4023-4028.
51. Zou X, et al. (2002) Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. Genes Dev 16(22): 2923-2934.